NIH/NEI BRDG-SPAN $3,000,000
Commercialization of iSONEP™, a Humanized Monoclonal Antibody against the Bioactive Lipid Sphingosine-1-Phosphate for the Treatment of AMD and other Ocular Disorders
2R44-CA110298-04 Sabbadini (Principal Investigator) 6/09-5/12 $3,000,000.
Commercialization of ASONEPTM, a Humanized Monoclonal Antibody Against the Pro-angiogenic and Tumorigenic Bioactive Lipid, Sphingosine-1-Phosphate.
2R44EY018020-02 Sabbadini (Co-Investigator). 12/1/07-12/01/09 $1,439,264.
Sphingomab Mitigates the Multiple Pathologies of Age-Related Macular Degeneration.
1R43GM088956-01 Sabbadini (Co-Investigator). 9/1/09-3/31/10. $152,724.
Structure Based Design of Humanized Monoclonal Antibodies that Recognize Bioactive Lipids.
1R43CA132395-01A2 Sabbadini, (Co-Investigator) 7/1/09-6/31/10. $139,523.
Development of therapeutic monoclonal antibody to the bioactive lipid lysophosphatidic acid.
Goldshmit Y, Matteo R, Sztal T, Ellett F, Frisca F, Moreno K, Crombie D, Lieschke GJ, Currie PD, Sabbadini RA, Pébay A. Blockage of lysophosphatidic acid signalling improves spinal cord injury outcomes. Am. J. Pathology. (in press), 2012.
Sabbadini R, Wojciak JM, Moreno K, Visentin B. Antibodies to bioactive lysophospholipids in Lysophospholipid Receptors: Signaling and Biochemistry ed. J. Chun, et al. John Wiley, 2012 (in press).
Ponnusamy S, Selvam SP, Mehrotra S, Kawamori T, Snider AJ, Obeid LM, Shao Y, Sabbadini R, Ogretmen B. Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO Mol Med. Jun 18. [Epub ahead of print], 2012.
Frisca F, Sabbadini RA, Goldshmit Y, Pebay A. Biological Effects of Lysophosphatidic Acid in the Nervous System. Int. Rev. Cellular and Mol. Biol. 2012;296:273-322, 2012.
Visentin B, Reynolds G, Sabbadini, R. Immunohistochemical detection of sphingosine-1-phosphate and sphingosine kinase-1 in human tissue samples. Methods Mol Biol. 2012;874:55-67, 2012.
Lukowski ZL, Min J, Beattie AR, Meyers CA, Levine MA, Stoller G, Schultz GS, Samuelson DA, Sherwood MB. Prevention of Ocular Scarring After Glaucoma Filtering Surgery Using the Monoclonal Antibody LT1009 (Sonepcizumab) in a Rabbit Model. J Glaucoma. 2011 Sep 22. [Epub ahead of print].
Fleming JK, Wojciak JM, Campbell MA, Huxford T. Biochemical and structural characterization of lysophosphatidic acid binding by a humanized monoclonal antibody. J Mol Biol. 2011 May 6;408 (3):462-76. Epub Mar 15.
Sabbadini, RA. Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration. Br J Pharmacol. 2010 Nov 22. [Epub ahead of print].
Wojciak, J., Zhu, N., Schuerenberg, K., Moreno, K., Shestowksy, W., Hiraiwa, M., Sabbadini, R., Huxford, T. The crystal structure of sphingosine-1-phosphate in complex with a Fab fragment reveals metal bridging of an antibody and its antigen. Proc. Nat. Acad. Sci. 2009 Oct 20; 106(42):17717-22. Epub Oct 7 2009.
O'Brien, N., Jones, ST., Williams, DG., Cunningham, HB., Moreno, K., Visentin, B., Gentile, A., Vekich, J., Shestowsky, W., Hiraiwa, M., Matteo, R., Cavalli, A., Grotjahn, D., Grant, M., Hansen, G., Campbell, MA., Sabbadini, R. Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. J Lipid Res. 2009 50, 2245-2257, Epub Jun 9 2009.
Gellings Lowe, N., Swaney, JS., Moreno, K., Sabbadini, R. Sphingosine-1-phosphate and sphingosine kinase are critical for TGF-alpha-stimulated collagen production by cardiac fibroblasts. Cardiovascular Res. 2009 May 1; 82 (2):303-12. Epub Feb 19 2009.
Caballero, S., Moreno, K., Stoller, G., Cavalli, A., Garland, W., Hansen, G., Sabbadini, R., Grant, M. Anti-sphingosine-1-phosphate monoclonal antibody inhibits angiogenesis and sub-retinal fibrosis in a murine model of laser induced choroidal neovascularization. Experimental Eye Research 2009 Mar; 88(3):367-77. Epub Aug 6 2008.
Swaney, J., Moreno, K., Gentile, A., Sabbadini, R., Stoller, G. Sphingosine-1-phosphate (S1P) is a novel fibrotic mediator in the eye. Experimental Eye Research 2008 Oct;87(4):367-75. Epub Jul 18 2008.
Visentin, B., Vekich, J., Sibbald, B., Cavalli, A., Matteo, R., Moreno, K., Garland, W., Lu, Y., Xing, F., Kumar, V., Mills, G., Sabbadini, R. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9:225-238. 2006.
Invited Speaker and Session Chair at the FASEB Summer Conference Lysophospholipid Mediators in Health and Disease. Luca, Italy.
Invited Keynote Speaker for the 6th Annual Protein Engineering Summit (PEGS). Boston, Massachusetts.
Invited Speaker Experimental Biology meeting (Molecular Pharmacology division of the American Society of Pharmacology & Experimental Therapeutics), Anaheim, CA.
April 24-28, 2010
Plenary Speaker Bioactive Lipids in Cancer, Inflammation and Related Diseases in Cancun, Mexico
October 25-28, 2009
Invited talk at the Medical University of South Carolina, Department of Biochemistry and Molecular Biology Hollings Cancer Center.
October 15, 2009
Invited Speaker at FASEB Summer Conference on Lysophospholipid Mediators in Health and Disease, Carefree, AZ.
June 28, 2009
Invited Speaker INSERM and IPBS, Institut de Pharmacologie et de Biologie Structurale of the CNRS. Toulouse, France
May 24, 2009
Invited Speaker American Assoc. of Cancer Researchers (AACR) 100th annual meeting. Denver, CO
April 20, 2009